National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 2) (PB 30 of 2020) (Cth)

PB 30 of 2020

National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 2)

National Health Act 1953

___________________________________________________________________________

I, THEA DANIEL, Assistant Secretary, Pricing and PBS Policy Branch, Technology Assessment and Access Division, Department of Health, delegate of the Minister for Health, make this Determination under section 85B of the National Health Act 1953.

Dated  30 March 2020

THEA DANIEL

Assistant Secretary

Pricing and PBS Policy Branch

Technology Assessment and Access Division

Department of Health

_________________________________________________________________________

1. Name of Instrument

(1)This Instrument is the National Health (Price and Special Patient Contribution) Amendment Determination 2020 (No. 2).

(2)This Instrument may also be cited as PB 30 of 2020.

1. Commencement

This Instrument commences on 1 April 2020.

1. Amendment of National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010)

Schedule 1 amends the National Health (Price and Special Patient Contribution) Determination 2010 (PB 109 of 2010).

Schedule 1     Amendments

1. Schedule 1, entry for Acarbose in the form Tablet 50 mg

(a)   omit from the column headed “Determined Price”:   18.14     substitute:             15.51

(b)omit from the column headed “Claimed Price”:   20.64     substitute:             17.65

1. Schedule 1, entry for Acarbose in the form Tablet 100 mg

(a)   omit from the column headed “Determined Price”:   25.69     substitute:             21.96

(b)omit from the column headed “Claimed Price”:   28.19     substitute:             24.10

1. Schedule 1, after entry for Fluoxetine in the form Tablet, dispersible, 20 mg (as hydrochloride)

Insert:

Fluticasone propionate	Pressurised inhalation containing fluticasone propionate 125 micrograms per dose, 120 doses (CFC-free formulation)	Inhalation by Mouth	Flixotide	1	15.65	18.44
Pressurised inhalation containing fluticasone propionate 250 micrograms per dose, 120 doses (CFC-free formulation)	Inhalation by Mouth	Flixotide	1	28.80	31.59

1. Schedule 1, entry for Levodopa with Carbidopa

(a)   omit from the column headed “Determined Price”:   25.77     substitute:             19.33

(b)omit from the column headed “Claimed Price”:   31.12     substitute:             23.34

1. Schedule 1, entry for Mirtazapine

Omit:

Tablet 15 mg (orally disintegrating)	Oral	Remeron SolTab	30	3.85	8.27
Tablet 30 mg	Oral	Avanza	30	3.35	8.00
Tablet 30 mg (orally disintegrating)	Oral	Remeron SolTab	30	5.13	9.55
Tablet 45 mg (orally disintegrating)	Oral	Remeron SolTab	30	7.72	12.14

Substitute:

Tablet 30 mg	Oral	Avanza	30	3.35	8.00
Tablet 45 mg (orally disintegrating)	Oral	Remeron SolTab	30	7.72	12.14

1. Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 20 mg

(a)   omit from the column headed “Determined Price”:   4.34        substitute:             3.83

(b)omit from the column headed “Claimed Price”:   7.60        substitute:             6.71

1. Schedule 1, entry for Olmesartan in the form Tablet containing olmesartan medoxomil 40 mg

(a)   omit from the column headed “Determined Price”:   9.21        substitute:             8.13

(b)omit from the column headed “Claimed Price”:   12.46     substitute:             11.00

1. Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 20 mg with hydrochlorothiazide 12.5 mg

(a)   omit from the column headed “Determined Price”:   5.75        substitute:             5.27

(b)omit from the column headed “Claimed Price”:   7.61        substitute:             6.97

1. Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 12.5 mg

(a)   omit from the column headed “Determined Price”:   10.65     substitute:             9.57

(b)omit from the column headed “Claimed Price”:   12.51     substitute:             11.24

[10] Schedule 1, entry for Olmesartan with hydrochlorothiazide in the form Tablet containing olmesartan medoxomil 40 mg with hydrochlorothiazide 25 mg

(a)   omit from the column headed “Determined Price”:   12.04     substitute:             11.00

(b)omit from the column headed “Claimed Price”:   13.90     substitute:             12.70

[11] Schedule 1, entry for Rosuvastatin in the form Tablet 5 mg (as calcium)

(a)   omit from the column headed “Determined Price”:   3.50        substitute:             2.45

(b)omit from the column headed “Claimed Price”:   5.50        substitute:             3.85

[12] Schedule 1, entry for Rosuvastatin in the form Tablet 20 mg (as calcium)

(a)   omit from the column headed “Determined Price”:   7.31        substitute:             5.11

(b)omit from the column headed “Claimed Price”:   9.31        substitute:             6.51

[13] Schedule 1, entry for Rosuvastatin in the form Tablet 40 mg (as calcium)

(a)   omit from the column headed “Determined Price”:   10.43     substitute:             7.30

(b)omit from the column headed “Claimed Price”:   13.33     substitute:             9.33